Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · IEX Real-Time Price · USD
0.430
-0.010 (-2.21%)
At close: Jul 19, 2024, 4:00 PM
0.490
+0.060 (13.95%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 4 employees as of December 31, 2023. The number of employees increased by 1 or 33.33% compared to the previous year.
Employees
4
Change (1Y)
1
Growth (1Y)
33.33%
Revenue / Employee
n/a
Profits / Employee
-$1,211,700
Market Cap
6.88M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| XWELL | 337 |
| Telesis Bio | 147 |
| Sunshine Biopharma | 44 |
| Pulmatrix | 22 |
| Notable Labs | 16 |
| GlucoTrack | 6 |
| Tenax Therapeutics | 6 |
| Virios Therapeutics | 4 |
CVKD News
- 5 days ago - Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024 - PRNewsWire
- 5 weeks ago - Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024 - PRNewsWire
- 7 weeks ago - Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients - PRNewsWire
- 2 months ago - Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 - PRNewsWire
- 2 months ago - Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update - PRNewsWire
- 3 months ago - Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 - PRNewsWire
- 3 months ago - Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts - PRNewsWire
- 4 months ago - Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update - PRNewsWire